Navigation Links
Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound

PRINCETON, NJ and NANJING, China, Dec. 13, 2011 /PRNewswire-Asia/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced that the companies have expanded the strategic partnership formed last year to include a second collaboration in a different therapeutic area. The companies agreed to co-develop BMS-795311, Bristol-Myers Squibb's preclinical small molecule inhibitor of the Cholesteryl Ester Transfer Protein (CETP).  Inhibiting CETP could potentially raise HDL (good cholesterol) levels and help prevent cardiovascular disease. This collaboration is expected to accelerate the delivery of clinical Phase IIa proof-of-concept by leveraging the complementary strengths of a premier Chinese pharmaceutical company and a global biopharmaceutical company.

Under the terms of the agreement, Simcere will receive exclusive rights to develop and commercialize BMS-795311 in China while Bristol-Myers Squibb will retain exclusive rights in all other markets.  The companies will together determine the strategic development plan to explore the potential of BMS-795311 to treat and prevent progression of cardiovascular disease. Simcere will run and fund initial development work.  Financial terms were not disclosed.

"We reached another important milestone in our partnership with Bristol-Myers Squibb by expanding the collaboration to a second program.  It further demonstrates our commitment and capabilities in building a sustainable development platform with our strategic partners. We are excited to continue the momentum and leverage our combined strengths in product development." commented Dr. Peng Wang, chief scientific officer, Simcere Pharmaceutical Group.  

"Simcere was the first company with which Bristol-Myers Squibb created a partnership under our Oyster Strategy to seed companies in key markets with promising investigational medicines of continued interest from our early pipeline," said Francis Cuss, M.D., senior vice president, Research, Bristol-Myers Squibb. "That partnership, focused on an oncology compound, has gone extremely well and we are excited to expand our relationship to include a second collaboration in another therapeutic area. Working together we are building on the strengths of both organizations to develop potential medicines and help patients."

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit or follow us on Twitter at

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective therapy, including cancer, strokes, cardiovascular diseases, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit

Bristol-Myers Squibb Forward Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products.  Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.  No forward-looking statement can be guaranteed.  Among other risks, there can be no guarantee that the compound described in this release will move from exploratory development into full product development, that clinical trials of this compound will support a regulatory filing, or that the compound will receive regulatory approval or become a commercially successful product. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.  Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Simcere Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filing with the U.S. Securities and Exchange Commission at Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


Bristol-Myers Squibb

Jennifer Fron Mauer (United States)
Tel:    609-252-6579

Stella Ling, (China)
Tel:    +86-21-2321-8218

John Elicker
Tel:    609-252-4611


Kate Tellier,
Brunswick Group (United States)
Tel:    212-333-3810

Yehong Zhang,
Simcere (Nanjing)
Tel: +86-25-8556-6666 ext. 8811

Yue Yu,
Brunswick Group (Beijing)
Tel: +86-10-5960-8600

Joseph Lo Chi-Lun,
Brunswick Group (Hong Kong)
Tel: +852-3512-5000

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2011 Results
2. Simcere Pharmaceutical Group to Announce Third Quarter 2011 Financial Results on Monday, November 14, 2011
3. Simceres Iremod Receives SFDA New Drug Approval
4. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
5. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
6. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
7. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
8. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
9. Simcere Announces Recent Progress of Qiangkes Registration
10. Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011
11. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
Post Your Comments:
(Date:10/9/2015)... -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) today announced ... Society of Emergency Medicine (EuSEM) meeting to be held October ... the Lingotto Congress Centre in Turin, Italy ... medicine practitioners in the world with over 2000 delegates in ... previously announced phase 2 bunionectomy trial will also be included.  ...
(Date:10/9/2015)... October 9, 2015 El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... los doctores Yutaka Kondo y ... Award 2015, se ha otorgado a los doctores ... ™ , una compañía biofarmacéutica global con sede enSuiza, presentará el ...
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. ... focused on gastrointestinal and cardio-renal diseases, today announced ... candidate, tenapanor, will be presented at the 2015 ... findings will include measures of sustained response in ... blind, placebo-controlled, randomized Phase 2 trial. The meeting ...
Breaking Medicine Technology:
... ,, NEW YORK , Aug. 3 ITelagen, a ... it was selected by Manhattan ,s Physician Group (MPG) to host, ... includes hosting of patient data in ITelagen,s SAS-70 Type II certified datacenter ... for staff members. , , ...
... PHILADELPHIA , Aug. 3 ... a safe, isotope-free alternative to traditional radiation therapy ... focus of 14 clinical research studies presented at ... Meeting.  According to Xoft, Inc., the clinical benefits ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... The Asthma and Allergy Foundation of America ... Control and Prevention (CDC) to improve the knowledge and skills of underserved adults with ... a project by the CDC and allows AAFA to continue vital efforts to educate ...
(Date:10/9/2015)... New Orleans, LA (PRWEB) , ... October 09, ... ... firm with offices serving New Orleans and the surrounding communities, is initiating a ... shelter and medical care for unwanted animals in southern Louisiana. , Animal ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... States, is welcoming individuals from all walks of life to save money on ... set price of $25 per month per medication, individuals and families can receive ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ViewPoint Center, ... Awareness Week. For many teenagers facing mental illness, the stigma associated with mental illness ... , ViewPoint Center understands the importance of supporting teens with mental illness ...
(Date:10/9/2015)... ... October 09, 2015 , ... Ryan ... and largest recreational dispensaries in Colorado, says the latest figures on the state’s ... and maturing into a legitimate industry. , Last month, according to ...
Breaking Medicine News(10 mins):
... vitamin D and multiple sclerosis in African Americans, a team ... discovered that vitamin D levels in the blood are lower ... Americans who do not. "It seems relatively clear," said ... Multiple Sclerosis Center, director of the UCSF Neurodiagnostics Center and ...
... May 27 (HealthDay News) -- Whether or not a woman ... seven years before she even conceives, new research suggests. ... that routine evaluations of blood sugar and body weight -- ... risk for the condition, according to the report published in ...
... to 10% of all breast cancers are monogenic in origin. ... BRCA1, BRCA2 or other high-risk genes. In this edition of ... 2011; 108(19): 323 30), Alfons Meindl of the Klinikum rechts ... the pathogenesis and treatment of hereditary breast and ovarian cancer ...
... 27 (HealthDay News) -- Youngsters who do not get enough ... overweight, a new study has found. Conversely, when ... mass index (BMI) and a significant drop in their risk ... lower BMIs resulted from differences in fat mass (not any ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, May ... in more sedentary jobs, they,re packing on the pounds, and ... epidemic, new research suggests. Staring at the computer for ... 120 to 140 fewer calories a day than they did ...
... EAST LANSING, Mich. While recent studies have shown ... women overturning physicians, long-held beliefs that the hormone ... by which estrogen induces high blood pressure was unclear. ... found long-term estrogen exposure generates excessive levels of the ...
Cached Medicine News:
The world's first automatic computation program analyzes massive amount of measurement data and computes "the most comfortable value" for the patient....
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
Maddox Rod, short handle (12cm)...
Snellen 10' Eye Test Chart....
Medicine Products: